The second strategy was treating the PMPs with ROT/AmA compounds, as the mitochondrial respiratory chain complex I and III inhibitors, before co-incubation with the CLL cell groups (63, 64). This evidence concerns the gene NDUFV1 and B-cell chronic lymphocytic leukemia.